Drugs / dnaJP1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07013110 | Jun 2025 → Nov 2028 expected | rheumatoid arthritis | Singapore Health Services | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dnaJP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07013110 ↗ |
| Action | Restore | “dnaJP1 works to restore the body's immune tolerance” NCT07013110 ↗ |
| Modality | Peptide | “dnaJP1 peptide. It is a manmade short protein” NCT07013110 ↗ |